文献速递细菌感染、耐药与抗菌药物

达巴万星体外暴露筛选出达巴万星不敏感和万古霉素中介的MRSA菌株

Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
PubMed 文献 · Clin Microbiol Infect · 2020-08-28

本研究利用体外PK/PD模型模拟单剂1500 mg达巴万星在5株MRSA和1株MSSA中的暴露,持续28天。结果显示达巴万星早期杀菌后出现再生长,所有模型均筛选出达巴万星MIC升高64-128倍的稳定突变株,且万古霉素和达帕托霉素MIC升高4-16倍并超过敏感折点,β-内酰胺MIC多下降但部分上升。突变基因常见walKR、apt、stp1和atl。

要点

  • 达巴万星长半衰期暴露在体外可筛选出达巴万星不敏感且万古霉素中介的MRSA突变株。
  • 筛选出的突变株对达帕托霉素交叉耐药,但对β-内酰胺敏感性多升高(跷跷板效应)。
  • 耐药突变常涉及walKR、apt、stp1和atl基因,与万古霉素中介和达帕托霉素不敏感相关。

核心结论

  • 在体外PK/PD模型中,达巴万星暴露筛选出对达巴万星、万古霉素和达帕托霉素敏感性降低的稳定突变株,且多数菌株对β-内酰胺敏感性增加。

研究设计与样本

  • 体外药代动力学/药效学模型模拟单剂1500 mg达巴万星的平均暴露(fCmax 9.9 μg/mL,β消除半衰期204小时),持续28天(672小时),测试5株MRSA和1株MSSA。

主要发现

  • 达巴万星在1-4天对多数菌株有杀菌作用,随后出现低敏感亚群再生长。
  • 达巴万星MIC升高8倍的菌株最早第4天检出,第28天所有模型均升高64-128倍。
  • 万古霉素和达帕托霉素MIC升高4-16倍,超过两者敏感折点。
  • β-内酰胺MIC通常下降2-8倍,提示达巴万星-β-内酰胺跷跷板效应,但某些菌株升高8倍以上。
  • 耐药分离株携带多种基因突变,最常见于walKR、apt、stp1和atl。

关键数值与推荐

  • 达巴万星单剂1500 mg模拟暴露参数:fCmax 9.9 μg/mL,β消除半衰期204小时。
  • 达巴万星MIC升高8倍最早第4天检出,第28天升高64-128倍。
  • 万古霉素和达帕托霉素MIC升高4-16倍,超过敏感折点。
  • β-内酰胺MIC通常下降2-8倍,部分菌株升高8倍以上。

临床怎么用

  • 提示达巴万星长半衰期暴露可能筛选出交叉耐药MRSA,临床需关注治疗中耐药出现。
  • β-内酰胺敏感性增加现象或可支持联合β-内酰胺治疗策略,但临床意义尚不明确。

局限性

  • 研究为体外PK/PD模型,结果不能直接外推至临床。
  • 仅测试5株MRSA和1株MSSA,菌株数量有限。
  • 临床意义尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Dalbavancin is a lipoglycopeptide active against methicillin-resistant Staphylococcus aureus (MRSA). Its long half-life (8.5-16 days) allows for once-weekly or single-dose treatments but could prolong the mutant selection window, promoting resistance and cross-resistance to related antimicrobials such as vancomycin. The objective of this study was to evaluate the capacity of post-distributional pharmacokinetic exposures of dalbavancin to select for resistance and cross-resistance in MRSA. METHODS: We simulated average, post-distributional exposures of single-dose (1500 mg) dalbavancin (fCmax 9.9 μg/mL, β-elimination t1/2 204 h) in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model for 28 days (672 h) against five MRSA strains and one methicillin-susceptible strain (MSSA). Samples were collected at least daily, and surviving colonies were enumerated and screened for resistance on drug-free and dalbavancin-supplemented medium respectively. Isolates from resistance screening plates were subjected to whole-genome sequencing (WGS) and susceptibly testing against dalbavancin, vancomycin, daptomycin, and six β-lactams with varying penicillin-binding protein (PBP) affinities. RESULTS: Dalbavancin was bactericidal against most strains for days 1-4 before regrowth of less susceptible subpopulations occurred. Isolates with eight-fold increases in dalbavancin MIC were detected as early as day 4 but increased 64-128-fold in all models by day 28. Vancomycin and daptomycin MICs increased 4-16-fold, exceeding the susceptibly breakpoints for both antibiotics; β-lactam MICs generally decreased by two-to eight-fold, suggesting a dalbavancin-β-lactam seesaw effect, but increased by eight-fold or more in certain isolates. Resistant isolates carried mutations in a variety of genes, most commonly walKR, apt, stp1, and atl. CONCLUSIONS: In our in vitro system, post-distributional dalbavancin exposures selected for stable mutants with reduced susceptibility to dalbavancin, vancomycin, and daptomycin, and generally increased susceptibility to β-lactams in all strains of MRSA tested. The clinical significance of these findings remains unclear, but created an opportunity to genotype a unique collection of dalbavancin-resistant strains for the first time. Mutations involved genes previously associated with vancomycin intermediate susceptibility and daptomycin non-susceptibility, most commonly walKR-associated genes.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Werth BJ, Ashford NK, Penewit K, et al. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2020. PMID: 32866650. doi:10.1016/j.cmi.2020.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。